FATE Q3 2021 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+88.2% YoY

Gross Profit

-$39M-273.5% margin

Operating Income

-$55M-384.0% margin

Net Income

-$43M-304.4% margin

EPS (Diluted)

$-0.45

QoQ Revenue Growth

+6.1%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$48M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$985M

Total Liabilities

$254M

Stockholders' Equity

$730M

Cash & Equivalents

$129M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$8M	+88.2%
Gross Profit	-$39M	-$23M	-68.2%
Operating Income	-$55M	-$31M	-73.5%
Net Income	-$43M	-$59M	+26.2%

Revenue Segments

Upfront Fee And Equity Premium

$4M100%